{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:00:26Z","timestamp":1789840826910,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13054-018-2001-5","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T00:26:34Z","timestamp":1522801594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["The use of mid-regional proadrenomedullin to identify disease severity and treatment response to sepsis - a secondary analysis of a large randomised controlled trial"],"prefix":"10.1186","volume":"22","author":[{"name":"the SepNet Critical Care Trials Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4948-1605","authenticated-orcid":false,"given":"Gunnar","family":"Elke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius Cameron","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Martin","family":"Brunkhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Briegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Reinhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Nierhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Jaschinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onnen","family":"Moerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Weyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Meybohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,21]]},"reference":[{"key":"2001_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"348","author":"GS Martin","year":"2003","unstructured":"Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546\u201354.","journal-title":"N Engl J Med"},{"key":"2001_CR2","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1001\/jama.2014.2637","volume":"311","author":"KM Kaukonen","year":"2014","unstructured":"Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308\u201316.","journal-title":"JAMA"},{"key":"2001_CR3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.CCM.0000194725.48928.3A","volume":"34","author":"JL Vincent","year":"2006","unstructured":"Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344\u201353.","journal-title":"Crit Care Med"},{"key":"2001_CR4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801\u201310.","journal-title":"JAMA"},{"key":"2001_CR5","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/cc8204","volume":"14","author":"JL Vincent","year":"2010","unstructured":"Vincent JL, Moreno R. Clinical review: scoring systems in the critically ill. Crit Care. 2010;14:207.","journal-title":"Crit Care"},{"key":"2001_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00134-007-0561-y","volume":"33","author":"B Temmesfeld-Wollbruck","year":"2007","unstructured":"Temmesfeld-Wollbruck B, Brell B, David I, et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med. 2007;33:703\u201310.","journal-title":"Intensive Care Med"},{"key":"2001_CR7","doi-asserted-by":"publisher","first-page":"R73","DOI":"10.1186\/cc13830","volume":"18","author":"HC Muller-Redetzky","year":"2014","unstructured":"Muller-Redetzky HC, Will D, Hellwig K, et al. Mechanical ventilation drives pneumococcal pneumonia into lung injury and sepsis in mice: protection by adrenomedullin. Crit Care. 2014;18:R73.","journal-title":"Crit Care"},{"key":"2001_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.surg.2006.05.017","volume":"141","author":"GJ Carrizo","year":"2007","unstructured":"Carrizo GJ, Wu R, Cui X, Dwivedi AJ, Simms HH, Wang P. Adrenomedullin and adrenomedullin-binding protein-1 downregulate inflammatory cytokines and attenuate tissue injury after gut ischemia-reperfusion. Surgery. 2007;141:245\u201353.","journal-title":"Surgery"},{"key":"2001_CR9","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1097\/01.CCM.0000190625.14268.09","volume":"33","author":"B Brell","year":"2005","unstructured":"Brell B, Hippenstiel S, David I, et al. Adrenomedullin treatment abolishes ileal mucosal hypoperfusion induced by Staphylococcus aureus alpha-toxin - an intravital microscopic study on an isolated rat ileum. Crit Care Med. 2005;33:2810\u2013016.","journal-title":"Crit Care Med"},{"key":"2001_CR10","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1097\/01.CCM.0000159194.53695.7A","volume":"33","author":"B Brell","year":"2005","unstructured":"Brell B, Temmesfeld-Wollbruck B, Altzschner I, et al. Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat ileum microcirculatory damage. Crit Care Med. 2005;33:819\u201326.","journal-title":"Crit Care Med"},{"key":"2001_CR11","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s13054-016-1540-x","volume":"20","author":"B Vigue","year":"2016","unstructured":"Vigue B, Leblanc PE, Moati F, et al. Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study. Crit Care. 2016;20:363.","journal-title":"Crit Care"},{"key":"2001_CR12","first-page":"281","volume":"53","author":"A Tyagi","year":"2009","unstructured":"Tyagi A, Sethi AK, Girotra G, Mohta M. The microcirculation in sepsis. Indian J Anaesth. 2009;53:281\u201393.","journal-title":"Indian J Anaesth"},{"key":"2001_CR13","first-page":"161","volume":"11","author":"G Hernandez","year":"2013","unstructured":"Hernandez G, Bruhn A, Ince C. Microcirculation in sepsis: new perspectives. Curr Vasc Pharmacol. 2013;11:161\u20139.","journal-title":"Curr Vasc Pharmacol"},{"key":"2001_CR14","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1097\/BCR.0000000000000508","volume":"38","author":"J Gille","year":"2017","unstructured":"Gille J, Ostermann H, Dragu A, Sablotzki A. MR-proADM: A new biomarker for early diagnosis of sepsis in burned patients. J Burn Care Res. 2017;38:290\u20138.","journal-title":"J Burn Care Res"},{"key":"2001_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jneuroim.2017.08.012","volume":"312","author":"A Bustamante","year":"2017","unstructured":"Bustamante A, Garc\u00eda-Berrocoso T, Penalba A, et al. Sepsis biomarkers reprofiling to predict stroke-associated infections. J Neuroimmunol. 2017;312:19\u201323.","journal-title":"J Neuroimmunol"},{"key":"2001_CR16","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/ijms18081796","volume":"18","author":"SO Decker","year":"2017","unstructured":"Decker SO, Sigl A, Grumaz C, et al. Immune-response patterns and next generation sequencing diagnostics for the detection of mycoses in patients with septic shock - results of a combined clinical and experimental investigation. Int J Mol Sci. 2017;18:1796. \n                    https:\/\/doi.org\/10.3390\/ijms18081796","journal-title":"Int J Mol Sci"},{"key":"2001_CR17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1471-2334-11-112","volume":"11","author":"WC Albrich","year":"2011","unstructured":"Albrich WC, Dusemund F, Ruegger K, et al. Enhancement of CURB65 score with proadrenomedullin (CURB65-A) for outcome prediction in lower respiratory tract infections: derivation of a clinical algorithm. BMC Infect Dis. 2011;11:112.","journal-title":"BMC Infect Dis"},{"key":"2001_CR18","first-page":"w13237","volume":"141","author":"WC Albrich","year":"2011","unstructured":"Albrich WC, Ruegger K, Dusemund F, et al. Optimised patient transfer using an innovative multidisciplinary assessment in Kanton Aargau (OPTIMA I): an observational survey in lower respiratory tract infections. Swiss Med Wkly. 2011;141:w13237.","journal-title":"Swiss Med Wkly"},{"key":"2001_CR19","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1183\/09031936.00113612","volume":"42","author":"WC Albrich","year":"2013","unstructured":"Albrich WC, Ruegger K, Dusemund F, et al. Biomarker-enhanced triage in respiratory infections: a proof-of-concept feasibility trial. Eur Respir J. 2013;42:1064\u201375.","journal-title":"Eur Respir J"},{"key":"2001_CR20","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/ajt.13478","volume":"16","author":"J Riera","year":"2016","unstructured":"Riera J, Senna A, Cubero M, et al. Primary graft dysfunction and mortality following lung transplantation: a role for proadrenomedullin plasma levels. Am J Transplant. 2016;16:634\u20139.","journal-title":"Am J Transplant"},{"key":"2001_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/CCM.0000000000000709","volume":"43","author":"A Schoe","year":"2015","unstructured":"Schoe A, Schippers EF, Struck J, et al. Postoperative pro-adrenomedullin levels predict mortality in thoracic surgery patients: comparison with Acute Physiology and Chronic Health Evaluation IV Score. Crit Care Med. 2015;43:373\u201381.","journal-title":"Crit Care Med"},{"key":"2001_CR22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jamainternmed.2016.2514","volume":"176","author":"F Bloos","year":"2016","unstructured":"Bloos F, Trips E, Nierhaus A, et al. Effect of sodium selenite administration and procalcitonin-guided therapy on mortality in patients with severe sepsis or septic shock: a randomized clinical trial. JAMA Intern Med. 2016;176:1266\u201376.","journal-title":"JAMA Intern Med"},{"key":"2001_CR23","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP\/SCCM Consensus Conference Committee. American College of Chest Physicians\/Society of Critical Care Medicine. Chest. 1992;101:1644\u201355.","journal-title":"Chest"},{"key":"2001_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/sim.4085","volume":"30","author":"MJ Pencina","year":"2011","unstructured":"Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11\u201321.","journal-title":"Stat Med"},{"key":"2001_CR25","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2213-2600(14)70061-X","volume":"2","author":"JL Vincent","year":"2014","unstructured":"Vincent JL, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014;2:380\u20136.","journal-title":"Lancet Respir Med"},{"key":"2001_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1007\/s00134-017-4782-4","volume":"43","author":"F Bloos","year":"2017","unstructured":"Bloos F, Ruddel H, Thomas-Ruddel D, et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. Intensive Care Med. 2017;43:1602\u201312.","journal-title":"Intensive Care Med"},{"key":"2001_CR27","first-page":"CD010959","volume":"1","author":"BN Andriolo","year":"2017","unstructured":"Andriolo BN, Andriolo RB, Salomao R, Atallah AN. Effectiveness and safety of procalcitonin evaluation for reducing mortality in adults with sepsis, severe sepsis or septic shock. Cochrane Database Syst Rev. 2017;1:CD010959.","journal-title":"Cochrane Database Syst Rev"},{"key":"2001_CR28","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.2353\/ajpath.2006.051104","volume":"168","author":"E Gonzalez-Rey","year":"2006","unstructured":"Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. Am J Pathol. 2006;168:1921\u201330.","journal-title":"Am J Pathol"},{"key":"2001_CR29","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1160\/TH07-02-0128","volume":"98","author":"B Temmesfeld-Wollbruck","year":"2007","unstructured":"Temmesfeld-Wollbruck B, Hocke AC, Suttorp N, Hippenstiel S. Adrenomedullin and endothelial barrier function. Thromb Haemost. 2007;98:944\u201351.","journal-title":"Thromb Haemost"},{"key":"2001_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1515\/cclm-2015-0243","volume":"54","author":"A Enguix-Armada","year":"2016","unstructured":"Enguix-Armada A, Escobar-Conesa R, La Torre AG, De La Torre-Prados MV. Usefulness of several biomarkers in the management of septic patients: C-reactive protein, procalcitonin, presepsin and mid-regional pro-adrenomedullin. Clin Chem Lab Med. 2016;54:163\u20138.","journal-title":"Clin Chem Lab Med"},{"key":"2001_CR31","first-page":"136","volume":"71","author":"D Andaluz-Ojeda","year":"2015","unstructured":"Andaluz-Ojeda D, Cicuendez R, Calvo D, et al. Sustained value of proadrenomedullin as mortality predictor in severe sepsis. J Inf Secur. 2015;71:136\u20139.","journal-title":"J Inf Secur"},{"key":"2001_CR32","doi-asserted-by":"publisher","first-page":"R816","DOI":"10.1186\/cc3885","volume":"9","author":"M Christ-Crain","year":"2005","unstructured":"Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care. 2005;9:R816\u201324.","journal-title":"Crit Care"},{"key":"2001_CR33","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00134-013-3056-z","volume":"39","author":"B Suberviola","year":"2013","unstructured":"Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibanez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013;39:1945\u201352.","journal-title":"Intensive Care Med"},{"key":"2001_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13613-017-0238-9","volume":"7","author":"D Andaluz-Ojeda","year":"2017","unstructured":"Andaluz-Ojeda D, Nguyen HB, Meunier-Beillard N, et al. Superior accuracy of mid-regional proadrenomedullin for mortality prediction in sepsis with varying levels of illness severity. Ann Intensive Care. 2017;7:15.","journal-title":"Ann Intensive Care"},{"key":"2001_CR35","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1097\/CCM.0b013e3181f17bf9","volume":"38","author":"P Kopterides","year":"2010","unstructured":"Kopterides P, Siempos II, Tsangaris I, Tsantes A, Armaganidis A. Procalcitonin-guided algorithms of antibiotic therapy in the intensive care unit: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2010;38:2229\u201341.","journal-title":"Crit Care Med"},{"key":"2001_CR36","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1473-3099(16)00053-0","volume":"16","author":"E de Jong","year":"2016","unstructured":"de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16:819\u201327.","journal-title":"Lancet Infect Dis"},{"key":"2001_CR37","doi-asserted-by":"publisher","first-page":"944","DOI":"10.3111\/13696998.2015.1064934","volume":"18","author":"MM Kip","year":"2015","unstructured":"Kip MM, Kusters R, IJzerman MJ, Steuten LM. A PCT algorithm for discontinuation of antibiotic therapy is a cost-effective way to reduce antibiotic exposure in adult intensive care patients with sepsis. J Med Econ. 2015;18:944\u201353.","journal-title":"J Med Econ"},{"key":"2001_CR38","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1186\/2047-783X-16-12-543","volume":"16","author":"MH Wilke","year":"2011","unstructured":"Wilke MH, Grube RF, Bodmann KF. The use of a standardized PCT-algorithm reduces costs in intensive care in septic patients - a DRG-based simulation model. Eur J Med Res. 2011;16:543\u20138.","journal-title":"Eur J Med Res"},{"key":"2001_CR39","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1097\/CCM.0000000000000526","volume":"42","author":"L Debiane","year":"2014","unstructured":"Debiane L, Hachem RY, Al Wohoush I, et al. The utility of proadrenomedullin and procalcitonin in comparison to C-reactive protein as predictors of sepsis and bloodstream infections in critically ill patients with cancer. Crit Care Med. 2014;42:2500\u20137.","journal-title":"Crit Care Med"},{"key":"2001_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1586\/ers.13.6","volume":"7","author":"S Haubitz","year":"2013","unstructured":"Haubitz S, Mueller B, Schuetz P. Streamlining antibiotic therapy with procalcitonin protocols: consensus and controversies. Expert Rev Respir Med. 2013;7:145\u201357.","journal-title":"Expert Rev Respir Med"},{"key":"2001_CR41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00134-003-1709-z","volume":"29","author":"M Garrouste-Orgeas","year":"2003","unstructured":"Garrouste-Orgeas M, Montuclard L, Timsit JF, Misset B, Christias M, Carlet J. Triaging patients to the ICU: a pilot study of factors influencing admission decisions and patient outcomes. Intensive Care Med. 2003;29:774\u201381.","journal-title":"Intensive Care Med"},{"key":"2001_CR42","doi-asserted-by":"publisher","first-page":"R128","DOI":"10.1186\/cc12807","volume":"17","author":"DW Johnson","year":"2013","unstructured":"Johnson DW, Schmidt UH, Bittner EA, Christensen B, Levi R, Pino RM. Delay of transfer from the intensive care unit: a prospective observational study of incidence, causes, and financial impact. Crit Care. 2013;17:R128.","journal-title":"Crit Care"},{"key":"2001_CR43","first-page":"308","volume":"22","author":"JM Pereira","year":"2016","unstructured":"Pereira JM, Azevedo A, Basilio C, Sousa-Dias C, Mergulhao P, Paiva JA. Mid-regional proadrenomedullin: an early marker of response in critically ill patients with severe community-acquired pneumonia? Rev Port Pneumol. 2016;22:308\u201314.","journal-title":"Rev Port Pneumol"},{"key":"2001_CR44","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1016\/j.ajem.2016.08.032","volume":"34","author":"C Miguez","year":"2016","unstructured":"Miguez C, Tomatis Souverbielle C, Haro A, et al. Evaluation of proadrenomedullin as a diagnostic or prognostic biomarker of acute appendicitis in children. Am J Emerg Med. 2016;34:2298\u2013305.","journal-title":"Am J Emerg Med"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-018-2001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13054-018-2001-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-018-2001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T09:04:27Z","timestamp":1557479067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-018-2001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,21]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1186\/s13054-018-2001-5","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,21]]},"assertion":[{"value":"15 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol of the SISPCT trial was approved by the ethics board of Jena University Hospital (Internal File No. 2242-03\/08). Written informed consent was obtained from all patients or their legal representatives.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual participant data are reported that would require consent from the participant (or legal parent or guardian for children) to publish.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors have provided information on potential conflicts of interests directly or indirectly related to the work submitted in the journal\u2019s disclosure forms. FB reported receiving lecture honoraria from biosyn, Gilead, and CSL Behring and public funding for the SISPCT trial to his department by the German Federal Ministry of Education and Research, and unrestricted research grants for the SISPCT trial from biosyn and Thermo Fisher Scientific. DCW is an employee of BRAHMS GmbH. KR reported receiving personal fees from Adrenomed and being a shareholder of InflaRx Jena. SK reported receiving lecture fees from Astellas, Basilea, biotest, CSL Behring, CytoSorbents, Fresenius, Gilead, MSD, Pfizer and Thermo Fisher Scientific and being a member of advisory boards for Astellas, Fresenius, Gilead, MSD, Novartis and Pfizer. AN reported receiving lecture honoraria from Thermo Fisher Scientific. All other authors declared that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"79"}}